A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults (CSL's IVV)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00562484 |
|
Recruitment Status :
Completed
First Posted : November 22, 2007
Results First Posted : September 12, 2011
Last Update Posted : November 21, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Influenza | Biological: CSL Limited Influenza Vaccine Biological: Placebo | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 7500 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Phase IV, Randomized, Observer-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in Adults Aged ≥ 18 to < 65 Years. |
| Study Start Date : | March 2008 |
| Actual Primary Completion Date : | November 2009 |
| Actual Study Completion Date : | January 2010 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: 1 |
Biological: CSL Limited Influenza Vaccine
A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0. |
| 2 |
Biological: Placebo
Placebo |
- CSL's IVV Overall Vaccine Efficacy (VE) Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection [ Time Frame: 2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 ]
Incidence of Laboratory Confirmed Influenza A/B infection was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / placebo recipient infection rate.
- CSL's IVV Vaccine Efficacy Versus Placebo Through Assessment of Incidence of Laboratory Confirmed Influenza A/B Infection Due to Strains Matched to Vaccine Strains [ Time Frame: 2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 ]
Incidence of laboratory confirmed influenza A/B infection due to strains matched to vaccine strains was assessed per the study population in the 2008 and 2009 Southern Hemisphere influenza seasons.
Vaccine efficacy = 100 x (1 - ratio of incidence rate). Ratio of incidence rate = active Study Vaccine recipient infection rate / Placebo recipient infection rate.
- Incidence of Influenza-like Illness (ILI) [ Time Frame: 2008 and 2009 Southern Hemisphere influenza seasons, until 30 November 2009 ]
The criteria for the protocol defined ILI were as follows:
- At least one respiratory symptom:
- cough, sore throat or nasal congestion
- And at least one systemic symptom:
- fever (as defined by oral temperature ≥ 37.8°C (100.0°F), or feverishness (as defined by participant's subjective feeling of fever), chills or body aches.
The CDC ILI case definition was the occurrence of fever (100°F [37.8°C] or higher) in conjunction with either cough or sore throat.
- Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2008 [ Time Frame: 21 days after study vaccination ]
- Percentage of Participants With a Minimum Post-vaccination Hemagglutination Inhibition (HI) Titer of 1:40, Year 2009 [ Time Frame: 21 days after study vaccination ]
- Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2008 [ Time Frame: 21 days after study vaccination ]Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.
- Percentage of Participants With Seroconversion 21 Days After Study Vaccination, Year 2009 [ Time Frame: 21 days after study vaccination ]Seroconversion rate: defined as the percentage of participants with either a pre-vaccination HI titer < 1:10 and a post-vaccination HI titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer.
- Geometric Mean Fold Increase in HI Titer 21 Days After Study Vaccination, Year 2008 [ Time Frame: 21 days after study vaccination ]Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.
- Geometric Mean Fold Increase in HI Titer Rate 21 Days After Study Vaccination, Year 2009 [ Time Frame: 21 days after study vaccination ]Geometric mean fold increase in HI titer was defined as the geometric mean titer (GMT) after vaccination divided by the GMT before vaccination.
- Frequency and Intensity of Local and Systemic Solicited Symptoms [ Time Frame: 5 days after study vaccination ]
Adverse event grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.
Fever Grade 1: ≥ 37.7°C - < 38.0°C (≥ 99.9 - < 100.4°F) Grade 2: ≥ 38.0°C - < 39.0°C (≥ 100.4 - < 102.2°F) Grade 3: ≥ 39.0°C (> 102.2°F)
- Frequency and Intensity of Unsolicited Adverse Events (UAEs) [ Time Frame: 21 days after study vaccination ]
UAE grading:
Grade 1 (mild): Symptoms were easily tolerated and did not interfere with daily activities.
Grade 2 (moderate): Discomfort was enough to cause some interference with daily activities.
Grade 3 (severe): Symptoms that prevented normal, everyday activities.
- Serious Adverse Events (SAEs) [ Time Frame: 180 days after study vaccination ]
An SAE was any untoward medical occurrence that at any dose:
- Resulted in death;
- Was life-threatening;
- Required an unexpected in-participant hospitalization or prolongation of existing hospitalization;
- Resulted in persistent or significant disability / incapacity;
- Was a congenital anomaly / birth defect; and / or
- Was medically significant (defined as an event that did not necessarily meet any of the SAE criteria, but was judged by the treating physician to potentially jeopardize the participant or require medical intervention to prevent one of the out
- New Onsets of Chronic Illness (NOCI) [ Time Frame: 180 days after study vaccination ]An NOCI was defined as the diagnosis of a chronic medical condition where the symptoms commenced or worsened following exposure to study vaccine and may have included those potentially controllable by medication (e.g., glaucoma, hypertension).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy males and females aged ≥ 18 to < 65 years at the time of vaccination
- Non pregnant/ non lactating females
Exclusion Criteria:
- Hypersensitivity to influenza vaccine or allergy to any components of the Study Vaccines
- Vaccination against influenza in the previous 6 months
- Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality
- Known history of Guillain-Barré Syndrome;
- Clinical signs of active infection and/or an oral temperature of ≥ 37.8 oC.
- History of neurological disorders or seizures
- Confirmed or suspected immunosuppressive condition or a previously diagnosed immunodeficiency disorder
- Current or recent immunosuppressive or immunomodulative therapy, including systemic corticosteroids
- Administration of immunoglobulins and/or any blood products;
- Participation in a clinical trial or use of an investigational compound;
- Vaccination with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior;
- Participants indicated to receive an influenza vaccine on an annual basis according to the local public health recommendations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00562484
Show 24 study locations
| Study Director: | Clinical Director Vaccines | Seqirus |
| Responsible Party: | Seqirus |
| ClinicalTrials.gov Identifier: | NCT00562484 |
| Other Study ID Numbers: |
CSLCT-USF-06-28 |
| First Posted: | November 22, 2007 Key Record Dates |
| Results First Posted: | September 12, 2011 |
| Last Update Posted: | November 21, 2017 |
| Last Verified: | October 2017 |
|
Influenza, Human Orthomyxoviridae Infections RNA Virus Infections |
Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |